my personal edition > attention deficit hyperactivity disorder > news


  E-Mail this DGDispatch to a colleague

DGDispatch

Long-Acting, Controlled-Release Methylphenidate Effective for ADHD in Adults: Presented at ECNP

By Jenny Powers

ISTANBUL, Turkey -- September 19, 2009 -- The long-acting osmotic controlled-release (OROS) formulation of methylphenidate (MPH) is effective for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults, according to a study presented here at the 22nd European College of Neuropsychopharmacology (ECNP) Congress.

Barbara Schaeuble MD, Janssen-Cilag, Neuss, Germany, presented the findings on September 13. She focused on the secondary outcomes of the study; primary endpoints were presented separately at another poster session.

Secondary endpoints included changes in the Conners' Adult ADHD Rating Scale-Self-Report: Short Version (CAARS-S:S); Responder; Sheehan Disability Scale (SDS) work questionnaire; Clinical Global Impression-Severity (CGI-S); and the ADHD Impact Model for Adults (AIMA).

The double-blind, placebo-controlled study included 226 patients 18 to 65 years of age who had chronic ADHD before age 7. Patients were randomised to receive placebo (n = 116) or OROS MPH (n = 110) for 7 weeks.

Doses began at 36 mg/day followed by weekly increases of 18 mg until the primary endpoint was achieved or until maximum dose was achieved. Titration was allowed for up to 5 weeks, followed by a 14-day observation period.

Patients receiving OROS MPH showed greater improvement over placebo in CAARS-S:S (P = .029) and by Responder (P = .009).

Patients receiving OROS MPH demonstrated good, but not statistically significant improvement on the SDS work questionnaire, CGI-S, and AIMA.

The long-acting, controlled formulation of MPH was well tolerated with no serious treatment-emergent adverse events observed.

Funding for this study was provided by Janssen-Cilag and Johnson & Johnson.

[Presentation title: Efficacy of OROS in a Randomized Controlled Trial in Adults With ADHD: Secondary Endpoints. Abstract P7.a.003]

E-Mail this DGDispatch to a colleague

To print, use this version